JGJan Willem M. Greve

Jan Willem M. Greve

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jan Willem M. Greve has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Impact of Duodenal-Jejunal Exclusion on Satiety Hormones

    by Charlotte de Jonge, Sander S. Rensen, Froukje J. Verdam, Royce P. Vincent, Steve R. Bloom, Wim A. Buurman, Carel W. le Roux, Nicole D. Bouvy, Jan Willem M. Greve

    Bariatric procedures that exclude the proximal small intestine lead to significant weight loss which is probably mediated by changes in hormones that alter appetite, such as peptide YY (PYY), ghrelin, cholecystokinin (CCK), and leptin. Here, the effect of the non-surgical duodenal-jejunal bypass liner (DJBL) on concentrations of hormones implicated in appetite control was investigated.


  • Open Access

    Genetic and epigenetic regulation of gene expression in fetal and adult human livers

    by Marc Jan Bonder, Silva Kasela, Mart Kals, Riin Tamm, Kaie Lokk, Isabel Barragan, Wim A Buurman, Patrick Deelen, Jan-Willem Greve, Maxim Ivanov, et al.

    The liver plays a central role in the maintenance of homeostasis and health in general. However, there is substantial inter-individual variation in hepatic gene expression, and although numerous genetic factors have been identified, less is known about the epigenetic factors. By analyzing the methylomes and transcriptomes of 14 fetal and 181 adult livers, we identified 657 differentially methylated genes with adult-specific expression, these genes were enriched for transcription factor binding sites of HNF1A and HNF4A. We also identified 1,000 genes specific to fetal liver, which were enriched for GATA1, STAT5A, STAT5B and YY1 binding sites. We saw strong liver-specific effects of single nucleotide polymorphisms on both methylation levels (28,447 unique CpG sites (meQTL)) and gene expression levels (526 unique genes (eQTL)), at a false discovery rate (FDR) < 0.05. Of the 526 unique eQTL associated genes, 293 correlated significantly not only with genetic variation but also with methylation levels. The tissue-specificities of these associations were analyzed in muscle, subcutaneous adipose tissue and visceral adipose tissue. We observed that meQTL were more stable between tissues than eQTL and a very strong tissue-specificity for the identified associations between CpG methylation and gene expression. Our analyses generated a comprehensive resource of factors involved in the regulation of hepatic gene expression, and allowed us to estimate the proportion of variation in gene expression that could be attributed to genetic and epigenetic variation, both crucial to understanding differences in drug response and the etiology of liver diseases.


  • Six Months of Treatment with the Endoscopic Duodenal-Jejunal Bypass Liner Does Not Lead to Decreased Systemic Inflammation in Obese Patients with Type 2 Diabetes

    by Charlotte de Jonge, Sander S. Rensen, Hedwig M. A. D’agnolo, Nicole D. Bouvy, Wim A. Buurman, Jan Willem M. Greve


  • Endoscopic Duodenal–Jejunal Bypass Liner Rapidly Improves Type 2 Diabetes

    by Charlotte de Jonge, Sander S. Rensen, Froukje J. Verdam, Royce P. Vincent, Steve R. Bloom, Wim A. Buurman, Carel W. le Roux, Nicolaas C. Schaper, Nicole D. Bouvy, Jan Willem M. Greve

    Bariatric procedures excluding the proximal small intestine improve glycemic control in type 2 diabetes within days. To gain insight into the mediators involved, we investigated factors regulating glucose homeostasis in patients with type 2 diabetes treated with the novel endoscopic duodenal–jejunal bypass liner (DJBL).


    • 1 January 2012
      • Vol. 156  (23) , A4630

    [Practice guideline for the treatment of morbid obesity].

    by Froukje J Verdam, Charlotte De Jonge, Jan Willem M Greve

    The increasing prevalence of obesity and its related comorbidities represents an increasing burden for the Dutch health care and requires effective therapy. The primary treatment of obesity consists of lifestyle interventions directed at lifestyle change; in morbidly obese subjects only bariatric surgery is cost-effective in the long term, with respect to both weight loss and reduction in comorbidity. There is a new Dutch multidisciplinary practice guideline on the treatment of morbid obesity, in which the following aspects are covered: indications for surgery, pre-operative policy advice, considerations for the type of operation, and the short and long term follow-up after bariatric surgery. Patients between 18 and 65 years old are eligible for bariatric surgery if they have a BMI ≥ 40 kg/m2 or a BMI ≥ 35 kg/m2 in the presence of comorbidity. In adolescents under 18 bariatric surgery should only be performed in a research setting; in patients older than 65 years bariatric surgery can be performed exceptionally, preferably in a centre with large experience.


  • The Surgical Treatment of Diabetic Obesity

    by Jeroen Nijhuis, Wim A. Buurman, Jan Willem M. Greve

    Morbid obesity is associated with serious co-morbidities as cardiovascular disease, insulin resistance (IR) and type 2 diabetes (T2DM). Conventional therapy for T2DM consists of weight loss and pharmacotherapy. Recently, surgery was suggested to be the best treatment for T2DM in morbid obese patients. This review will focus on the effects of bariatric surgery on T2DM. The outcomes of different bariatric techniques will be discussed. Moreover, the question why weight loss is advantageous in treating T2DM will be addressed. In this view, the effect of decreased nutrient intake, decreased intracellular fatty acid accumulation as well as decreased body fat mass on T2DM are discussed.